{"id":"igy","safety":{"commonSideEffects":[{"rate":null,"effect":"Respiratory adverse events (cough, bronchospasm)"},{"rate":null,"effect":"Gastrointestinal events"},{"rate":null,"effect":"Hypersensitivity reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"IgY antibodies are derived from immunized chickens and recognize multiple epitopes on P. aeruginosa lipopolysaccharide and other surface antigens. By binding these bacterial components, IgY prevents bacterial adhesion, reduces biofilm formation, and enhances clearance of the pathogen in cystic fibrosis airways. This polyclonal approach provides broad coverage against diverse P. aeruginosa strains.","oneSentence":"IgY is a polyclonal immunoglobulin Y (chicken antibody) therapeutic that targets and neutralizes Pseudomonas aeruginosa virulence factors and biofilm components in the respiratory tract.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:45:56.986Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Cystic fibrosis with chronic Pseudomonas aeruginosa respiratory infection"}]},"trialDetails":[{"nctId":"NCT06973889","phase":"PHASE2","title":"Evaluation of IgY Antibody Efficacy in Egg Yolk Against Helicobacter Pylori in Bacterial Elimination and Clinical Symptoms Improvement of Gastrointestinal Patients","status":"COMPLETED","sponsor":"Mashhad University of Medical Sciences","startDate":"2023-12-04","conditions":"HELICOBACTER PYLORI INFECTIONS, Gastrointestinal Disease","enrollment":60},{"nctId":"NCT06702280","phase":"PHASE1","title":"Assessing the Safety of an IGY Supplement on the Gut Microbiome","status":"NOT_YET_RECRUITING","sponsor":"Nimble Science Ltd.","startDate":"2025-02","conditions":"Healthy, Microbiome","enrollment":20},{"nctId":"NCT05656482","phase":"","title":"Ability of a Cat Food to Reduce Respiratory Symptoms in Cat Allergic Patients","status":"UNKNOWN","sponsor":"MASK-air SAS","startDate":"2022-05-06","conditions":"Rhinitis, Allergic","enrollment":50},{"nctId":"NCT04567810","phase":"PHASE1","title":"Safety, Tolerability, and Pharmacokinetics of Anti-Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Chicken Egg Antibody (IgY) (COVID-19)","status":"COMPLETED","sponsor":"Stanford University","startDate":"2020-09-18","conditions":"Covid19","enrollment":48},{"nctId":"NCT04025983","phase":"NA","title":"Effectiveness of GastimunHp Plus in Supporting the Treatment of Peptic Ulcer Disease With Helicobacter Pylori Infection","status":"TERMINATED","sponsor":"Institute of Gastroenterology and Hepatology, Vietnam","startDate":"2019-11-01","conditions":"Helicobacter Pylori Infection, Peptic Ulcer","enrollment":190},{"nctId":"NCT02721355","phase":"NA","title":"Effect of Chicken Egg Antibody (IgY) on Patients With Chronic Gastritis","status":"COMPLETED","sponsor":"Immunology Research Institute in Gifu","startDate":"2013-06","conditions":"Chronic Gastritis Caused by Helicobacter Pylori","enrollment":84},{"nctId":"NCT02972463","phase":"PHASE1, PHASE2","title":"The Influence of IgY Max on Inflammatory Markers and the Gut Microbiome","status":"COMPLETED","sponsor":"Igy Nutrition, LLC","startDate":"2017-01-13","conditions":"Healthy","enrollment":100},{"nctId":"NCT03058224","phase":"NA","title":"Efficacy and Safety of IGN-ES001 in Chronic Widespread Pain With or Without Fibromyalgia","status":"COMPLETED","sponsor":"IgNova GmbH","startDate":"2017-02-16","conditions":"Chronic Widespread Pain, Fibromyalgia","enrollment":230},{"nctId":"NCT01455675","phase":"PHASE3","title":"Efficacy Study of IgY (Antibody Against Pseudomonas) in Cystic Fibrosis Patients","status":"COMPLETED","sponsor":"Mukoviszidose Institut gGmbH","startDate":"2011-10","conditions":"Cystic Fibrosis","enrollment":164},{"nctId":"NCT02385773","phase":"NA","title":"Impact of the Nutritional Product PTM202 on Acute and Long-Term Recovery From Childhood Diarrheal Disease","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2015-03","conditions":"Diarrhea","enrollment":321},{"nctId":"NCT00633191","phase":"PHASE1, PHASE2","title":"Anti-pseudomonas IgY to Prevent Infections in Cystic Fibrosis","status":"COMPLETED","sponsor":"Immunsystem AB","startDate":"2003-11","conditions":"Cystic Fibrosis, Infection, Pseudomonas Aeruginosa","enrollment":14},{"nctId":"NCT02705885","phase":"NA","title":"IgY Efficacy on Periodontitis Patients","status":"COMPLETED","sponsor":"Immunology Research Institute in Gifu","startDate":"2014-06","conditions":"Chronic Periodontitis","enrollment":60},{"nctId":"NCT02341352","phase":"PHASE3","title":"Three Measures for the Prevention of Carious Lesions in Preschool Children","status":"UNKNOWN","sponsor":"Zhejiang University","startDate":"2013-04","conditions":"Dental Caries","enrollment":500},{"nctId":"NCT01890889","phase":"NA","title":"Study of Changes in Total Cholesterol Levels as a Function of Consuming a Supplement Designed to Improve Cardiovascular Health","status":"UNKNOWN","sponsor":"Integrative Health Technologies, Inc.","startDate":"2013-07","conditions":"Cholesterol, Hyperlipidemia, Hypercholesteremia","enrollment":150}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"NAUSEA"},{"count":1,"reaction":"VOMITING"}],"_approvalHistory":[],"publicationCount":1855,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["PsAer-IgY"],"phase":"phase_3","status":"active","brandName":"IgY","genericName":"IgY","companyName":"Mukoviszidose Institut gGmbH","companyId":"mukoviszidose-institut-ggmbh","modality":"Small molecule","firstApprovalDate":"","aiSummary":"IgY is a polyclonal immunoglobulin Y (chicken antibody) therapeutic that targets and neutralizes Pseudomonas aeruginosa virulence factors and biofilm components in the respiratory tract. Used for Cystic fibrosis with chronic Pseudomonas aeruginosa respiratory infection.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}